ArticleDiabetology international2019
A case of variant hemoglobin (Hb Agenogi) with type 2 diabetes mellitus showed high HbA1c levels measured by immunoassay due to enhanced antigenicity.
Article in Diabetology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- A case of α-chain variant hemoglobin (Hb Chad) with falsely high HbA1c levels measured by immunoassay.Diabetology international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HbA1c is a widely utilized biomarker for the management of diabetes mellitus. The presence of variant hemoglobins might interfere with HbA1c measurement using different methods. We herein describe Hb Agenogi (β90Glu → Lys) with type 2 diabetes mellitus whose HbA1c measured by immunoassay (IA) showed falsely high levels while HbA1c measured by high-performance liquid chromatography (HPLC) in the standard mode (SM) showed falsely low levels. To clarify the cause of the falsely high-IA-HbA1c levels, HbA1c was measured by various methods. Glycated albumin was slightly higher than the reference range. HbA1c measured by HPLC in the variant mode, affinity assay and enzymatic assay showed the range (mean ± 2SD: 6.0-6.8%) in this case. However, HbA1c measured by several HPLC-SMs showed falsely low levels (4.1-4.4%). IA-HbA1c using an antibody manufactured by Fujirebio Inc. showed falsely high levels (7.3-8.2%); whereas, IA-HbA1c using an antibody manufactured by Roche Ltd. showed the expected range (6.2-6.5%). In the case of Hb Agenogi, IA-HbA1c using an antibody manufactured by Fujirebio yielded falsely high levels. The mutation at codon 90 of the β-globin chain might enhance antigenicity of the N-terminal peptide region and, therefore, lead to falsely high-HbA1c levels in IA-HbA1c.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.